Clinical Trial Update: Tarlox and Sotorasib in Patients With KRAS G12C Mutations [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating Tarlox and sotorasib in KRAS G12C-mutant non-small cell lung cancer has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarlox
• sotorasib (sotorasib)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-12-16